Polyethylene-glycolylated isoniazid conjugate for reduced toxicity and sustained release

Therapeutic Delivery

Volumn 2, Issue 2, 2011, Pages 205-212

  Kakkar, Dipti ^a,b   Tiwari, Anjani K ^a   Chuttani, Krishna ^a   Kumar, Raj ^a   Mishra, Krishnanand ^a   Singh, Harpal ^b   Mishra, Anil K ^a  

^a INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

^b All India Institute of Medical Sciences   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ISONIAZID; MACROGOL; POLYETHYLENE GLYCOLYLATED ISONIAZID CONJUGATE; TECHNETIUM 99M; TECHNETIUM 99M POLYETHYLENE GLYCOLYLATED ISONIAZID CONJUGATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL INFECTION; BIOACCUMULATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SYNTHESIS; GAMMA SCINTIGRAPHY; INFRARED SPECTROSCOPY; ISOTOPE LABELING; MASS SPECTROMETRY; MOLECULAR WEIGHT; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RABBIT; STAPHYLOCOCCUS AUREUS;

EID: 79954466183     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.10.97     Document Type: Article

References (15)

1. Basso LA, da Silva LH, Fett-Neto AG, et al. The use of biodiversity as source of new chemical entities against defined molecular targets for treatment of malaria, tuberculosis, and T-cell mediated diseases - a review. Mem. Inst. Oswaldo. Cruz. 100(6), 475-506 (2005). (Pubitemid 41626647)
2. US Centers for Disease Control and Prevention. Treatment of tuberculosis. American Thoracic Society, CDC, and Infectious Diseases Society of America. Morbidity and Mortality Weekly Report 52(RR-11), 1-77 (2003).
3. Zhangand Y, Young DB. Molecular mechanisms of isoniazid: a drug at the front line of tuberculosis control. Trends Microbiol. 1(3), 109-113 (1993). (Pubitemid 23187175)
4. Gokhale YA, Vaidya M, Rathod NN. Isoniazid toxicity presenting as status epilepticus and severe metabolic acidosis. J. Assoc. Physicians India 57, 70-71 (2009).
5. Sensi P, Grassi GG. Antimycobacterial Agents. In: Burger's Medicinal Chemistry, Drug Discovery and Development, 6th Edition. Abraham DA (Ed.). Wiley Publishers, NJ, USA 807-879 (2003).
6. Anderson JM, Kim SW, Kopecek J. Self-regulating insulin delivery systems. III In vivo studies. In: Advances in Drug Delivery Systems, 6. (Eds). Elsevier, Amsterdam, Holland 143-152 (1986).
7. Kydonieus AF. Fundamental concepts of controlled release. In: Controlled Release Technologies: Methods, Theory and Applications. Vol I and II. (Ed.). CRC Press, Boca Raton, FL, USA 7 (1980).
8. Giammona G, Carlisi B, Palazzo. Reaction of a,b-poly(N-hydroxyethyl)-dl- aspatamide with derivatives of carboxylic acids. J. Polym. Sci. Polym. Chem. Ed. 25, 2813 (1987).
9. Giammona G, Giannola LI, Carlisi B. Synthesis of polymeric derivatives of isoniazid: characterization and in vitro release from a water soluble adduct with polysuccinimide. Chem. Pharm. Bull. 37, 1106-1108 (1989). (Pubitemid 19144149)
10. Giammona G, Giannola LI, Carlisi B, Bajardi ML. Synthesis of macromolecular prodrugs of procaine, histamine and isoniazid. Chem. Pharm. Bull. 37, 2245-2247 (1989). (Pubitemid 19226544)
11. Bhadra D, Bhadra S, Jain P, Jain NK. Pegnology: a review of PEGylated systems. Pharmazie 57, 5 (2002).
12. Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation. Adv. Drug Del. Rev. 54, 459 (2002).
13. Cruz ML, Gil MH. Antituberculosis macromolecular prodrugs: part I. Isoniazid conjugates with poly(ethylene glycol) derivatives. J. Bio. Comp. Poly. 13, 146 (1998).
14. Hazari PP, Chuttani K, Kumar N, et al. Synthesis and biological evaluation of isonicotinic acid hydrazide conjugated with diethyelenetriaminepentaacetic acid for infection imaging. Open Nucl. Med. J. 1, 33 (2009).
15. Kakkar D, Tiwari AK, Verma J, Mishra AK. Kinetic and mechanistic significance of the chemical activation of ciprofloxacin for conjugation chemistry. Int. J. Chem. Kinet. 41, 349-356 (2009).